GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » ROA %

Alivus Life Sciences (NSE:ALIVUS) ROA % : 17.76% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Alivus Life Sciences's annualized Net Income for the quarter that ended in Dec. 2024 was ₹5,478 Mil. Alivus Life Sciences's average Total Assets over the quarter that ended in Dec. 2024 was ₹30,849 Mil. Therefore, Alivus Life Sciences's annualized ROA % for the quarter that ended in Dec. 2024 was 17.76%.

The historical rank and industry rank for Alivus Life Sciences's ROA % or its related term are showing as below:

NSE:ALIVUS' s ROA % Range Over the Past 10 Years
Min: 14.91   Med: 18.82   Max: 19.84
Current: 14.91

During the past 6 years, Alivus Life Sciences's highest ROA % was 19.84%. The lowest was 14.91%. And the median was 18.82%.

NSE:ALIVUS's ROA % is ranked better than
93.15% of 1037 companies
in the Drug Manufacturers industry
Industry Median: 2.08 vs NSE:ALIVUS: 14.91

Alivus Life Sciences ROA % Historical Data

The historical data trend for Alivus Life Sciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences ROA % Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROA %
Get a 7-Day Free Trial 19.56 18.89 18.74 18.05 16.96

Alivus Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.09 13.74 15.64 12.36 17.76

Competitive Comparison of Alivus Life Sciences's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alivus Life Sciences's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's ROA % distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's ROA % falls into.



Alivus Life Sciences ROA % Calculation

Alivus Life Sciences's annualized ROA % for the fiscal year that ended in Mar. 2024 is calculated as:

ROA %=Net Income (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=4708.88/( (27021.47+28504.12)/ 2 )
=4708.88/27762.795
=16.96 %

Alivus Life Sciences's annualized ROA % for the quarter that ended in Dec. 2024 is calculated as:

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=5478.4/( (30848.59+0)/ 1 )
=5478.4/30848.59
=17.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2024) net income data. ROA % is displayed in the 30-year financial page.


Alivus Life Sciences  (NSE:ALIVUS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=5478.4/30848.59
=(Net Income / Revenue)*(Revenue / Total Assets)
=(5478.4 / 25673.76)*(25673.76 / 30848.59)
=Net Margin %*Asset Turnover
=21.34 %*0.8323
=17.76 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Alivus Life Sciences ROA % Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alivus Life Sciences Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines